Burnet Institute Manager for Commercial Development and Industry Engagement, Serina Cucuzza believes her appointment to the board of AusBiotech reflects the biotechnology industry’s keen interest in closer engagement with Australia’s major research bodies.

Ms Cucuzza was one of three new directors appointed to the board of AusBiotech – Australia’s biotechnology industry organisation – at its Annual General Meeting on the Gold Coast this week.

AusBiotech represents more than 3000 members in the life sciences including therapeutics, medical technology, food technology and agricultural, environmental and industrial sectors.

Ms Cucuzza said she was pleased with her appointment and excited about the opportunities it presents, both personally, and for Burnet.

“I think the most important thing is that I can bring a different perspective to the board, coming from a different part of the sector, the academic research sector where a lot of the innovations that support the industry are incubated and come from,” Ms Cucuzza said.

“This reflects the changing environment of the industry where a lot of the pharma and big companies are starting to look more closely at what’s coming out of our research centres and universities.”

“They want to get engaged earlier and I can help provide that perspective.”

“My appointment will provide me with greater exposure to the industry which will not only help my learning opportunities but also allow more opportunities for Burnet Institute.”

In her Burnet role, Ms Cucuzza is involved in the commercialisation of novel technologies developed from the Institute’s research.

This includes managing the Institute’s IP portfolio; sourcing funding; negotiating deals and managing spin out companies.

She is also involved in projects of strategic importance to Burnet including biotechnology-related activities in China and is a director of Access Point of Care, a multi-national initiative that applies the Institute’s capabilities in novel point-of-care diagnostics in resource-constrained settings.